ibrutinib,rituximab
abbvie,janssen
[' ibru', 'cll', 'nhl', 'ritux', 'lymphoma', 'dlbcl']
 presenting results of triangle study of addition of ibrutinib to rchop &amp; rdhap therapy. benefit seen in all groups but maintenance rituximab added nothing. autograft seems to have been superseded. #ash22 plenary session. 
Clinical Haematologist, marrow transplanter. Past President World WMDA and WBMT. Editor-in-Chief Internal Medicine Journal.